TrialClinical pharmacokinetics2024

Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation.

Alex Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.